Medicine and Dentistry
Acute Myeloid Leukemia
100%
Disease
34%
Drug Response
30%
Venetoclax
30%
Risk Stratification
27%
Prognostication
18%
Thrombotic Thrombocytopenic Purpura
15%
Thrombocytopenic Purpura
15%
Leukemia
15%
Prevalence
15%
Chemotherapy-Induced Nausea and Vomiting
15%
Breast Cancer
15%
Hematopoietic Stem Cell
15%
Headache
15%
Bone Marrow Microenvironment
15%
Aplastic Anemia
15%
Hemophagocytic Syndrome
15%
Cell Function
15%
Cell Transplantation
15%
T Cell
15%
Atypical Hemolytic Uremic Syndrome
15%
Musculoskeletal Disease
15%
Acute Myelogenous Leukemia
15%
Malignant Neoplasm
11%
Androgen
10%
Aromatase Inhibitor
10%
Arthralgia
10%
Hormone Therapy
10%
Myalgia
10%
Adverse Event
10%
Hypomethylating Agent
9%
High Risk Population
9%
Induction Chemotherapy
8%
Drug Sensitivity
7%
Cell Maturation
7%
Signal Transduction
7%
Stem Cell
7%
Drive
7%
Chemotherapy
7%
Immune Response
7%
Clinical Pathway
7%
Targeted Therapy
7%
Gene Mutation
7%
Azacitidine
6%
Transplantation
6%
Ex Vivo
6%
Functional Genomics
6%
Transcriptomics
6%
Overall Survival
6%
Bone Marrow Failure
5%
Keyphrases
Acute Myeloid Leukemia
84%
Venetoclax
30%
European LeukemiaNet
23%
Leukemia Therapy
20%
Risk Stratification
19%
Survival Prognostication
16%
FLT3-ITD
15%
Pharmacological Targeting
15%
Activation Syndrome
15%
Chemotherapy-induced Diarrhea
15%
Organ-specific Toxicity
15%
MicroRNA-155 (miR-155)
15%
MLN4924
15%
Clinical Correlation
15%
Bone Marrow Microenvironment
15%
Pevonedistat
15%
T Cell Activation
15%
Combined Sensitivity
15%
NEDD8-activating Enzyme
15%
Oncogene Dependency
10%
Hypomethylating Agents
9%
IDH2 Inhibitor
7%
Mode of Resistance
7%
Gene mutation
7%
Reclassification
7%
Intermediate Risk
7%
Azacytidine
6%
MicroRNA-29b
6%
HIT-6 Score
5%
Immature Myeloid Cells
5%
High-risk Disease
5%
Mutation Testing
5%
Cell Proliferation
5%
New Drug Targets
5%
Outcome Prediction
5%
Musculoskeletal Adverse Effects
5%
Cell State
5%
Genetic Studies
5%
Allogeneic Transplant
5%
Prognostic Tool
5%
Novel Therapies
5%
Induction Treatment
5%
Bone Marrow Failure
5%
Clonal Disorder
5%
Cytogenetic Assay
5%
Improved Outcomes
5%
CAR-NK Cells
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
61%
Malignant Neoplasm
27%
Leukemia
16%
Disease
16%
Syndrome
15%
Diarrhea
15%
Enzyme Inhibitor
15%
Breast Cancer
15%
Pevonedistat
15%
Headache
15%
microRNA 155
15%
Chemotherapy Induced Nausea and Vomiting
15%
Thrombocytopenic Purpura
15%
Immunotherapy
15%
Venetoclax
15%
Musculoskeletal Disease
15%
Hemolytic Uremic Syndrome
15%
Thrombotic Thrombocytopenic Purpura
15%
Prevalence
15%
Arthralgia
10%
Aromatase Inhibitor
10%
Myalgia
10%
Adverse Event
10%
Androgen
10%
Azacitidine
6%
Musculoskeletal Pain
5%
Fragility Fracture
5%
Side Effect
5%
Hormone Cancer Therapy
5%
Endocrine Therapy
5%
Symptomatology
5%
Cancer Growth
5%
Aromatase
5%